pain-management-internal-medicine-2019-posters-abstracts

37 / 46

Pain Management 2019 & Internal Medicine 2019 International Journal of Anesthesiology & Pain Medicine
ISSN: 2471-982X Page 75
JOINT EVENT
7th Edition of International Conference on
Pain Management
8th Edition of International Conference on
Internal Medicine &
Patient Care
&
March 25-26, 2019
Rome, Italy
Int J Anesth Pain Med 2019, Volume 5
DOI: 10.21767/2471-982X-C1-006
Combined effect of Baclofen and Acamprosate in
experimental models of peripheral neuropathic pain in
Wistar rats
Varun Vikas Vij
DMC and H Ludhiana, India
Neuropathic pain (NP) is defined as pain associated
withdamageor permanent alterationof theperipheral
or central nervous system. Current drug treatment for
the management of neuropathic pain associated with
various adverse effects. The present study was designed
to investigate the combined effect of acamprosate and
baclofen in experimental model of peripheral neuropathic
pain in Wistar rats.
Material & Methods: Neuropathic pain was induced by
chronic constriction injured (CCI) of sciatic nerve in rats.
A camprosate (100 and 200 mg/kg P.O.) and baclofen
(10 and 20 mg/kg P.O.) was given in different groups for
14 days starting on 7th day post sciatic nerve ligation.
Further combination of acamprosate (100 mg/kg P.O.)
and baclofen (10mg/kgP.O.) was also given to one group.
On 1th, 3rd, 7th, 14th and 21st day behavioral parameters
like mechanical allodynia and thermal hyperalgesia were
assessed. Then animals were sacrificed on 22nd day and
biochemical parameters (GSH, LPO, catalase, nitrite and
SOD) were assessed.
Results: Ligation of sciatic nerve significantly induced
mechanical allodynia and thermal hyperalgesia with
increase in oxidative stress (increase in LPO, nitrite) and
decline of anti-oxidant enzyme levels (catalase, sod,
GSH) in sciatic nerve homogenate. A camprosate (100
and 200 mg/kg P.O.) and baclofen (10 and 20 mg/kg P.O.)
attenuated all the behavioral and biochemical parameters
alone and/or combination.